Full Library
Mycobacterial Infections Potentiated by Biologics
Resource type
Journal Article
Authors/contributors
- Calabrese, Cassandra (Author)
- Winthrop, Kevin L. (Author)
Title
Mycobacterial Infections Potentiated by Biologics
Abstract
Biologic therapies have revolutionized the treatment of immune-mediated inflammatory
diseases but are associated with an increased risk of serious and opportunistic infections,
including tuberculosis and nontuberculous mycobacterial disease. Despite this increased
risk, the overall risk-benefit ratio remains favorable with appropriate screening
and risk assessment. Further population-based studies are needed to establish the
risk of tuberculosis and nontuberculous mycobacterial disease with the new biologics.
This article highlights the incidence and drug-specific risk of tuberculous and nontuberculous
mycobacterial infection in the setting of biologics, screening and prevention, and
treatment of latent tuberculosis in this setting.
Publication
Infectious Disease Clinics
Date
2020/06/01
Volume
34
Issue
2
Pages
413-423
Journal Abbr
Infectious Disease Clinics
Accessed
9/1/21, 3:45 PM
ISSN
0891-5520, 1557-9824
Language
English
Library Catalog
Extra
Publisher: Elsevier
PMID: 32444014
Citation
Calabrese, C., & Winthrop, K. L. (2020). Mycobacterial Infections Potentiated by Biologics. Infectious Disease Clinics, 34(2), 413–423. https://doi.org/10.1016/j.idc.2020.02.011
HEME-ONC AND CELLULAR THERAPIES
Link to this record